- Open
- 2591.00
- High
- 2595.23
- Low
- 2545.00
- Close
- 2563.50
- Change
- -7.00 (-0.27%)
- Volume
- 799,714
⌘K
| 22 May 2025 | Annual Report 2025 - Updated | |
| 22 May 2025 | Annual Report 2025 | |
| 16 May 2024 | Annual Report 2024 |
3i is a company that operates in two distinct areas, Private Equity and Infrastructure, with a focus on key investment markets in northern Europe and North America.
| 22 May 2025 | Annual Report 2025 - Updated | |
| 22 May 2025 | Annual Report 2025 | |
| 16 May 2024 | Annual Report 2024 |
3i is a company that operates in two distinct areas, Private Equity and Infrastructure, with a focus on key investment markets in northern Europe and North America.
| 8 Apr 2026 |
| Morning briefing: FTSE confirms Vietnams promotion to emerging market; Intl Biotechnology hails frenetic dealmaking” after Soleno bid; plus 3i Group |
| 7 Apr 2026 | Next better positioned than Primark and 3i's Action for a consumer downturn, says analyst |
| 2 Apr 2026 | March Madness: How the Iran war hit investment companies – the top risers and fallers over one month and first quarter |
| 27 Mar 2026 | Morning briefing: Actions US expansion plans spook 3i investors; Manulife managers to work with Geiger Counter duo; Achilles to consult shareholders after Spire Health gambit |
| 26 Mar 2026 | 3i shares fall 16% after Action update, with US entry planned |
| 26 Mar 2026 | Morning briefing: SpaceX to file IPO prospectus; 3i falls on Action update; Intl Biotechnology boosted by Terns bid; Golden Prospect considers management proposals |
Baroness Noakes and 2 other people have interests in this issuer
| 8 Apr 2026 |
| Morning briefing: FTSE confirms Vietnams promotion to emerging market; Intl Biotechnology hails frenetic dealmaking” after Soleno bid; plus 3i Group |
| 7 Apr 2026 | Next better positioned than Primark and 3i's Action for a consumer downturn, says analyst |
| 2 Apr 2026 | March Madness: How the Iran war hit investment companies – the top risers and fallers over one month and first quarter |
| 27 Mar 2026 | Morning briefing: Actions US expansion plans spook 3i investors; Manulife managers to work with Geiger Counter duo; Achilles to consult shareholders after Spire Health gambit |
| 26 Mar 2026 | 3i shares fall 16% after Action update, with US entry planned |
| 26 Mar 2026 | Morning briefing: SpaceX to file IPO prospectus; 3i falls on Action update; Intl Biotechnology boosted by Terns bid; Golden Prospect considers management proposals |
Baroness Noakes and 2 other people have interests in this issuer
